A Murine experimental models in carcinogenesis studies are efficient?
DOI:
https://doi.org/10.31686/ijier.vol8.iss1.2153Keywords:
Neoplasms, Immunology, Neoplasm Transplantation, OncogenesisAbstract
Economic and social development has essential repercussions on the health of populations, as it alters the morbidity and mortality profile and favors the increase in exposures and risks to human health, especially the risk of cancer. Cancer is considered a significant public health problem worldwide, and remains with high incidence rates, being considered a complex disease, with multifactorial causes. The permanent incidence rates of prostate cancer prove to be one of the most prevalent, considered the second most common cancer in men worldwide, and a leading cause of deaths from chronic noncommunicable diseases. Among the different types of cancer, prostate cancer has been the subject of great scientific interest. In this context, animal models are valuable for studying cancer-related aspects, the use of animal models has the potential to increase our understanding of carcinogenesis, tumor biology, and the impact of specific molecular events on tumor biology. Animal models with specific human cancer characteristics can be used to test cancer prevention and treatment strategies. In this review, we aim to show how the use of animal models as an essential tool in the study of the molecular mechanisms of carcinogenesis.
Downloads
References
[2]. BRASIL. Ministério da Saúde. Secretaria de Assistência à Saúde. Instituto Nacional de Câncer. Programa nacional de controle do câncer de colonrretal: documento de consenso. - Rio de Janeiro. INCA, 2018.
[3]. World Health Organization, Global Action plan for the prevention and control of noncommunicable diaseases 2013-2020. 2013
[4]. G.A.S. Mendonça. Câncer na população feminina brasileira. Rev. Saúde Pública. 1993. v. 27, n.1, p.68-75. http://dx.doi.org/10.1590/S0034-89101993000100011
[5]. M.R. Guerra, C.V.M. Gallo, G.A.S. Mendonça. Risco de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev. Brasileira de Cancerologia. 2005. v. 5, n.3, p. 227-234. https://pdfs.semanticscholar.org/c4c6/060c4fd66294e1517cff64fabde16dc7b4be.pdf
[6]. M. V. Nunes, E.H. Tajara. Efeitos tardios dos praguicidas organoclorados no homem. Rev. Saúde Pública. 1998 v.32,n. 4, p. 372-384. http://dx.doi.org/10.1590/S0034-89101998000400011
[7]. World Health Organization. Visão Global do Câncer, 2019.
[8]. C.R. Daleck, A.B. De Nardi. Oncologia Em Cães e Gatos - 2ª Ed. Rio de janeiro: Roca; 2016.
[9]. P.D.S. Quijada, P.A. Fernandes, D.S. Oliveira, B.M.O. Santos.Câncer de próstata: retrato de uma realidade de pacientes em tratamento. Rev enferm UFPE on line. 2017. v.11, (Supl. 6), p. 2490-9.
[10]. American Cancer Society. [Internet]. 2015. Disponível em: https://www.cancer.org/es/investigacion/datos-y-estadisticas-sobre-el-cancer-entre-los-hispanos.html. Acesso em: 10 de dez 2019.
[11]. J.S. Araújo, V.M. Conceição, M.M.F. Zago. Masculinidades transitórias no adoecimento pelo câncer de próstata. Rev. Latino-Am. Enfermagem. 2019. v. 27, n. 3224, p.1-9. http://dx.doi.org/10.1590/1518-8345.3248.3224
[12]. L.J. James, G.Wong, J.C.Craig, C.S. Hanson, A. Ju, K. Howard. Men’s perspectives of prostate cancer screening: A systematic review of qualitative studies. PLoS One. 2017. v.12, n.11, p. 1-23. DOI: 10.1371/journal.pone.0188258
[13]. A.E. Romanzini, M.G. Pereira, C. Guilherme, A.J. Cologna, E.C. Carvalho. Predictors of well-being and quality of life in men who underwent radical prostatectomy: longitudinal study. Rev. Latino-Am. Enfermagem. 2018. v. 26, n. 3031, p.1-14. http://dx.doi.org/10.1590/1518-8345.2601.3031
[14]. J.G. Clohessy, P.P. Pandolfi. Mouse hospital andco-clinical trialp roject—from bench to bed side .Nat. Rev. Clin. Oncol. 2015. 12, 491–498. doi: 10.1038/nrclinonc.2015.62
[15]. M.M. Grabowska, D.J. DeGraff, X. Yu, R.J. Jin, Z. Chen, A.D. Borowsky, R.J. Matusik. Mouse Models of Prostate Cancer: Picking the Best Model for the Question. Cancer Metastasis Rev. 2014 September ; 33(0): 377–397. doi:10.1007/s10555-013-9487-8. doi: 10.1007/s10555-013-9487-8
[16]. R.L.Johnson, J.C. Fleet. Animal Models of corectal Cancer. Cancer Metastasis Rev. 2013. v.32, n. 0, p. 39-67. doi: 10.1007/s10555-012-9404-6.
[17]. G.P. Dunn, L.J. Old, R.D. Schreiber. The immunobiology of cancer immune surveillance and immune editing. Immunity. 2004. v.21, n. 2, p. 137-48. https://doi.org/10.1016/j.immuni.2004.07.017
[18]. C. Pantaleão, A. Luchs. Câncer e modelos experimentais de tumores murinos. Ver Inst Adolfo Lutz. 2010. V. 69, n. 4, p. 439-45. http://periodicos.ses.sp.bvs.br/scielo.php?script=sci_arttext&pid=S0073-98552010000400001&lng=pt&nrm=iso
[19]. N. Sengupta, T.S. MacFie, T.T. MacDonald, D. Pennington, A.R. Silver. Cancer immuno editing and “spontaneus” tumor regression. Pathol Res Pract. 2010. v. 206, n. 1, p. 1-8.
[20]. S.I. Park, S.J. Kimm, L.K. McCauley, G.E. Gallick. Pre-Clinical Mouse Models of Human Prostate Cancer and their Utility in Drug Discovery. Curr Protoc Pharmacol. 2010 December 1; 51: 14.15–14.15.27. doi:10.1002/0471141755.ph1415s51.
[21]. M. Ittmann, J. Huang, E. Radaelli, P.Martin, S. Signoretti, R. Sullivan, B.W. Simons, J.M. Ward, B.D. Robinson, G.C. Chu, M. Loda, G. Thomas, A. Borowsky, R.D. Cardiff. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Research Online. 2013. v.73, n. 9, p. 2718-3. disponívelem: https://cancerres.aacrjournals.org/content/73/9/2718.full-text.pdf
[22]. M.M. Shen, C. abate-shen. molecular genetics of prostate câncer: new prospects for old challenges. Genes dev. 2010. doi: 10.1101/gad.1965810.
[23]. D. Lin, H. Xue, Y. Wang, R. Wu, A. Watahiki, X. Dong, H. Cheng, A.W.Wyatt, C.C. Collins, P.W. Gout, Y. Wang. Next generation patient-derived prostate cancer xenograft models. Asian J Androl. 2014. v. 16, n. 3, p. 407-412. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023366/
[24]. Y. Wang, J.X. Wang, H. Xue, D. Lin, X. Dong, P.W. Gout, X. Gao, J. Pang. Subrenal capsule grafting technology in human câncer modeling and translational câncer research. Differentiation. 2015. 91:15–19. doi: 10.1016/j.diff.2015.10.012
[25]. N.M Navone, M.E. Labate, P. Troncoso, C.L. Pisters, A.C.V. Eschenbach, C.J. Logothetis. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. O Jornal de Urologia. 1999. v. 161, Edição 1, p. 304-308. PMID: 10037428
[26]. J. Pavese, I.M. Ogden, R.C. Bergan. An Orthotopic Murine Model of Human Prostate Cancer Metastasis. Journal of Visualized Experiments. p.1-9. 2013 doi: 10.3791/50873.
[27]. Y. Huang, C. Cheng, C. Zhang, Y. Zhang, M. Chen, D.W. Strand, M. Jiang. Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. Asian Journal of Urology. 2016. 3:64-74. https://doi.org/10.1016/j.ajur.2016.02.004
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Eliza Miranda Ramos, Antônio Carlos de Abreu, Evair Moisés de Lima Santiago, Gislaine Recaldes de Abreu, Marcelo Barbosa Neves, Rondon Ramalho
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyrights for articles published in IJIER journals are retained by the authors, with first publication rights granted to the journal. The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author for more visit Copyright & License.
How to Cite
